Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Myeloid 1 Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

pembrolizumab 65 Nivolumab 58 Magnetic Resonance Spectroscopy 53 enzalutamide 39 Abiraterone Acetate 37 Radiosurgery 36 Gemcitabine 35 Specimen Handling 32 Radiotherapy 32 Ipilimumab 32 Androgen Antagonists 32 Prednisone 31 apalutamide 28 Cisplatin 28 Docetaxel 27 Leuprolide 26 atezolizumab 25 Carboplatin 25 durvalumab 23 cabozantinib 23 darolutamide 20 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 19 olaparib 18 Goserelin 17 Radiation 16 Gonadotropin-Releasing Hormone 16 Biopsy 16 gallium 68 PSMA-11 15 Pluvicto 15 avelumab 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Rehabilitation × Genitourinary × Clear all

NCT06238596 2025-10-03

ReCaP

Azienda USL Reggio Emilia - IRCCS

Phase NA Active not recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡